# A Case of Spontaneous Regression of Primary Tumor after Adrenalectomy for Primary Lung Cancer with Synchronous Adrenal Metastasis

**Authors:** Hisaya Chikaraishi, Ryu Kanzaki, Hironobu Samejima, Masao Kobayashi, Julian Horiguchi, Tomohiro Maniwa, Hidetoshi Satomi, Keiichiro Honma, Jiro Okami

PMC · DOI: 10.70352/scrj.cr.25-0379 · Surgical Case Reports · 2025-08-13

## TL;DR

A patient with lung cancer and adrenal metastasis showed spontaneous regression of the primary tumor after surgery for the adrenal lesion.

## Contribution

This case report documents a rare instance of spontaneous regression of non-small cell lung cancer following adrenalectomy.

## Key findings

- The primary lung tumor was pathologically absent after surgical removal of the adrenal metastasis.
- Postoperative imaging showed a reduction in the size of the primary tumor.
- The patient remained recurrence-free for 5 months after surgery.

## Abstract

Adrenal metastasis from primary lung cancer is relatively common, occurring in approximately 5%–10% of clinical cases. Long-term survival can be achieved through surgical resection of adrenal metastases in addition to primary lesions. Spontaneous regression of cancer is defined as the partial shrinkage or complete disappearance of cancer following no treatment or treatment considered ineffective against cancer. Spontaneous regression of non-small cell lung cancer (NSCLC) is rare. Here, we describe a case of NSCLC with adrenal metastasis, in which the primary tumor exhibited spontaneous regression and was pathologically absent following surgical treatment of the metastatic lesion.

A 59-year-old male patient was referred to our department with elevated carcinoembryonic antigen levels and an abnormal opacity on chest CT. Contrast-enhanced CT revealed a 2-cm lesion in the right upper lobe of the lung and a 4.5-cm mass in the right adrenal gland. Bronchoscopic biopsy confirmed non-small cell carcinoma (cT1bN0M1b, cStage IVA). As the adrenal metastasis was considered oligometastatic based on 18F-fluorodeoxyglucose PET/CT and head MRI, surgical resection of both the primary lung lesion and the adrenal metastasis was planned. Laparoscopic right adrenalectomy was performed, and histological examination confirmed adrenal metastasis from lung cancer. Postoperatively, no new metastases were detected, and CT demonstrated a reduction in the size of the primary lesion. Robot-assisted right upper lobectomy with lobe-specific nodal dissection was subsequently performed. Pathological examination revealed no malignant findings in the resected right upper lobe. The patient was discharged without complications and remains recurrence-free 5 months after surgery.

This report presents a case of primary lung cancer with adrenal metastasis in which the primary tumor underwent spontaneous regression and was pathologically absent following surgical treatment of the metastasis.

## Linked entities

- **Diseases:** non-small cell lung cancer (MONDO:0005233)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, ENO2 (enolase 2) [NCBI Gene 2026] {aka HEL-S-279, NSE}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, NR5A1 (nuclear receptor subfamily 5 group A member 1) [NCBI Gene 2516] {aka AD4BP, ELP, FTZ1, FTZF1, POF7, SF-1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, SF1 (splicing factor 1) [NCBI Gene 7536] {aka BBP, D11S636, MBBP, ZCCHC25, ZFM1, ZNF162}, MLANA (melan-A) [NCBI Gene 2315] {aka MART-1, MART1}
- **Diseases:** infectious diseases (MESH:D003141), Primary (MESH:D010538), Inflammatory (MESH:D007249), Lung Cancer (MESH:D008175), of the adrenal mass (MESH:C536030), NSCLC (MESH:D002289), lung (MESH:D008171), fibrosarcoma (MESH:D005354), atelectasis (MESH:D001261), adrenal tumors (MESH:D000310), pStage IVA (MESH:C538167), squamous cell carcinoma (MESH:D002294), large-cell neuroendocrine carcinoma (MESH:D018287), necrotic (MESH:D009336), PRESENTATION (MESH:D001946), adenocarcinoma (MESH:D000230), inflammatory pseudotumors (MESH:D006104), fibrosis (MESH:D005355), blood loss (MESH:D016063), adrenal lesion (MESH:D000307), Adrenal Metastasis (MESH:D009362), infections (MESH:D007239), neoplastic lesion (MESH:D009062), toxicity (MESH:D064420), lymphadenopathy (MESH:D008206), Tumor (MESH:D009369)
- **Chemicals:** 18F-fluorodeoxyglucose (MESH:D019788), ACKNOWLEDGMENTS (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12343202/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12343202/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12343202/full.md

---
Source: https://tomesphere.com/paper/PMC12343202